ReviewVaccine2008
Discrimination between host and pathogens by the complement system.
Review in Vaccine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 93 citations in OpenAlex.
- Discovery and characterization of vertebrate sialoglycan-binding proteins.Seminars in immunology · 2025Review
- The specific contributions of factor H and factor I in controlling fluid phase activation of the alternative complement pathway.Scientific reports · 2025Article
- Complement or insult: the emerging link between complement cascade deficiencies and pathology of myeloid malignancies.Journal of leukocyte biology · 2024Review
- Glycoengineering with neuraminic acid analogs to label lipooligosaccharides and detect native sialyltransferase activity in gram-negative bacteria.Glycobiology · 2024Article
- COVID-19 microthrombosis: unusually large VWF multimers are a platform for activation of the alternative complement pathway under cytokine storm.International journal of hematology · 2022Review
- Is It Possible to Intervene in the Capacity ofFrontiers in immunology · 2021Review
- Quantification of Factor H Mediated Self vs. Non-self Discrimination by Mathematical Modeling.Frontiers in immunology · 2020Article
- Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway.Frontiers in immunology · 2020Review
- Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.Frontiers in immunology · 2020Review
- Article
- Transcriptome analysis of Aeromonas hydrophila infected hybrid sturgeon (Huso dauricus×Acipenser schrenckii).Scientific reports · 2018Article
- Deficiency of complement factor H-related proteins and autoantibody-positive hemolytic uremic syndrome in an infant with combined partial deficiencies and autoantibodies to complement factor H and ADAMTS13.Clinical kidney journal · 2018Article
- Article
- Properdin: A multifaceted molecule involved in inflammation and diseases.Molecular immunology · 2018Review
- Brain microvascular endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells.The Journal of biological chemistry · 2018Article
- Circulating proteomic patterns in AF related left atrial remodeling indicate involvement of coagulation and complement cascade.PloS one · 2018Article
- Complement Component C3 Binds to the A3 Domain of von Willebrand Factor.TH open : companion journal to thrombosis and haemostasis · 2018Article
- Venom fromJournal of immunology research · 2018Article
- Gonococcal lipooligosaccharide sialylation: virulence factor and target for novel immunotherapeutics.Pathogens and disease · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Pathogen-specific complement activation requires direct recognition of pathogens and/or the absence of complement control mechanisms on their surfaces. Antibodies direct complement activation to potential pathogens recognized by the cellular innate and adaptive immune systems. Similarly, the plasma proteins MBL and ficolins direct activation to microorganisms expressing common carbohydrate structures. The absence of complement control proteins permits amplification of complement by the alternative pathway on any unprotected surface. The importance of complement recognition molecules (MBL, ficolins, factor H, C3, C1q, properdin, and others) to human disease are becoming clear as analysis of genetic data and knock out animals reveals links between complement proteins and specific diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.